NCT06826196Phase 1/2Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
A Phase 1B/2A, Intraindividual Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution for Intradermal Injection in Subjects With Alopecia Areata
In the register
The register attaches this trial to ALD-102 (Aldena Therapeutics), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Aldena Therapeutics
- Participants (registry)
- 24
- Start
- March 2025
- Primary completion
- October 2026
- Study completion
- December 2026 (planned)
- Last registry update
- March 2026
- Countries
- United States, Canada
Conditions studied: Alopecia Areata (AA)
Interventions: ALD-102 Solution, Placebo or Control
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.